Role of promyelocytic leukemia protein in host antiviral defense

Journal of Interferon and Cytokine Research

Volumn 31, Issue 1, 2011, Pages 145-158

  Geoffroy, Marie Claude ^a   Chelbi Alix, Mounira K ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CASEIN KINASE II; DAXX PROTEIN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 3; ISOPROTEIN; NUCLEIC ACID BINDING PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN ISG15; PROTEIN P53; PROTEIN UBC9; RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADENOVIRUS; APOPTOSIS; CELL NUCLEUS INCLUSION BODY; DNA DAMAGE; GENE EXPRESSION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HOST RESISTANCE; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA VIRUS A; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RABIES VIRUS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SIMIAN FOAMY VIRUS; TRANSCRIPTION REGULATION; UBIQUITINATION;

ANIMALS; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTERFERONS; INTRANUCLEAR INCLUSION BODIES; NUCLEAR PROTEINS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; VIRUS DISEASES;

RNA VIRUSES;

EID: 78651471295     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0111     Document Type: Review

References (121)

1. Adamson AL, Kenney S. 2001. Epstein-barr virus immediateearly protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol 75(5):2388-2399.
2. Ahn JH, Hayward GS. 1997. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J Virol 71(6):4599-4613.
3. Ahn JH, Hayward GS. 2000. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection. Virology 274(1):39-55.
4. Asper M, Sternsdorf T, Hass M, Drosten C, Rhode A, Schmitz H, Gunther S. 2004. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol 78(6):3162-3169.
5. Bailey D, OHare P. 2005. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling. Biochem J 392(Pt 2):271-281.
6. Bell P, Brazas R, Ganem D, Maul GG. 2000. Hepatitis delta virus replication generates complexes of large hepatitis delta antigen and antigenomic RNA that affiliate with and alter nuclear domain 10. J Virol 74(11):5329-5336.
7. Bernardi R, Papa A, Pandolfi PP. 2008. Regulation of apoptosis by PML and the PML-NBs. Oncogene 27(48):6299-6312.
8. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. 2004. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6(7):665-672.
9. Best JL, Ganiatsas S, Agarwal S, Changou A, Salomoni P, Shirihai O, Meluh PB, Pandolfi PP, Zon LI. 2002. SUMO-1 protease- 1 regulates gene transcription through PML. Mol Cell 10(4):843-855.
10. Bloch DB, Chiche JD, Orth D, de la Monte SM, Rosenzweig A, Bloch KD. 1999. Structural and functional heterogeneity of nuclear bodies. Mol Cell Biol 19(6):4423-4430.
11. Bloch DB, Nakajima A, Gulick T, Chiche JD, Orth D, de La Monte SM, Bloch KD. 2000. Sp110 localizes to the PML-Sp100 nuclear body and may function as a nuclear hormone receptor transcriptional coactivator. Mol Cell Biol 20(16):6138-6146.
12. Blondel D, Kheddache S, Lahaye X, Dianoux L, Chelbi-Alix MK. 2010. Resistance to rabies virus infection conferred by the PMLIV isoform. J Virol 84(20): 10719-10726.
13. Blondel D, Regad T, Poisson N, Pavie B, Harper F, Pandolfi PP, De The H, Chelbi-Alix MK. 2002. Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies. Oncogene 21(52):7957-7970.
14. Bonilla WV, Pinschewer DD, Klenerman P, Rousson V, Gaboli M, Pandolfi PP, Zinkernagel RM, Salvato MS, Hengartner H. 2002. Effects of promyelocytic leukemia protein on virus-host balance. J Virol 76(8):3810-3818.
15. Borden KL, Campbell Dwyer EJ, Salvato MS. 1998. An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. J Virol 72(1):758-766.
16. Brand P, Lenser T, Hemmerich P. 2010. Assembly dynamics of PML nuclear bodies in living cells. PMC Biophys 3(1):3.
17. Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F, Mothes W, Hazan U, Transy C, Pancino G, Nisole S. 2009. Human TRIM gene expression in response to interferons. PLoS One 4(3):e4894.
18. Chee AV, Lopez P, Pandolfi PP, Roizman B. 2003. Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol 77(12):7101-7105.
19. Chelbi-Alix MK, de The H. 1999. Herpes virus induced proteasome- dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18(4):935-941.
20. Chelbi-Alix MK, Pelicano L, Quignon F, Koken MHM, Venturini L, Stadler M, Pavlovic J, Degos L, de Thé H. 1995. Induction of the PML protein by interferons in normal and APL cells. Leukemia 9:2027-2033.
21. Chelbi-Alix MK, Quignon F, Pelicano L, Koken MHM, de The H. 1998. Resistance to virus infection conferred by the interferoninduced promyelocytic leukemia protein. J Virol 72:1043-1051.
22. Chelbi-Alix MK, Vidy A, El Bougrini J, Blondel D. 2006. Rabies viral mechanisms to escape the IFN system: the viral protein P interferes with IRF-3, Stat1, and PML nuclear bodies. J Interferon Cytokine Res 26(5):271-280.
23. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A, de The H. 2006. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res 66(12):6192-6198.
24. Crowder C, Dahle O, Davis RE, Gabrielsen OS, Rudikoff S. 2005. PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood 105(3):1280-1287.
25. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. 1990. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel ranscribed locus. Nature 347(6293):558-561.
26. Djavani M, Rodas J, Lukashevich IS, Horejsh D, Pandolfi PP, Borden KL, Salvato MS. 2001. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J Virol 75(13):6204-6208.
27. Doucas V, Ishov AM, Romo A, Juguilon H, Weitzman MD, Evans RM, Maul GG. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev 10(2):196-207.
28. Dror N, Rave-Harel N, Burchert A, Azriel A, Tamura T, Tailor P, Neubauer A, Ozato K, Levi BZ. 2007. Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J Biol Chem 282(8):5633-5640.
29. Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de The H, Hay RT, Freemont PS. 1999. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 112 (Pt 3):381-393.
30. Dyck JA, Maul GG, Miller WH, Chen JD, Kakizuka A, Evans RM. 1994. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76(2): 333-343.
31. Eldin P, Papon L, Oteiza A, Brocchi E, Lawson TG, Mechti N. 2009. TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. J Gen Virol 90(Pt 3):536-545.
32. El Mchichi B, Regad T, Maroui MA, Rodriguez MS, Aminev A, Gerbaud S, Escriou N, Dianoux L, Chelbi-Alix MK. 2010. SUMOylation promotes PML degradation during EMCV infection. J Virol 2010 84(22):11634-11645.
33. Evdokimov E, Sharma P, Lockett SJ, Lualdi M, Kuehn MR. 2008. Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3. J Cell Sci 121(Pt 24): 4106-4113.
34. Everett RD. 2001. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20(49):7266-7273.
35. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89(6-7): 819-830.
36. Everett RD, Freemont P, Saitoh H, Dasso M, Orr A, Kathoria M, Parkinson J. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J Virol 72(8):6581-6591.
37. Everett RD, Lomonte P, Sternsdorf T, van Driel R, Orr A. 1999. Cell cycle regulation of PML modification and ND10 composition. J Cell Sci 112 (Pt 24):4581-4588.
38. Everett RD, Maul GG. 1994. HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J 13(21):5062-5069.
39. Everett RD, Parada C, Gripon P, Sirma H, Orr A. 2008. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J Virol 82(6):2661-2672.
40. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14(16):2015-2027.
41. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19(22):6185-6195.
42. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU. 2007. TRIM25 RINGfinger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446(7138):916-920.
43. Gao B, Duan Z, Xu W, Xiong S. 2009. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50(2):424-433.
44. Geoffroy MC, Hay RT. 2009. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol 10(8): 564-568.
45. Gongora R, Stephan RP, Zhang Z, Cooper MD. 2001. An essential role for Daxx in the inhibition of B lymphopoiesis by type I interferons. Immunity 14(6):727-737.
46. Gresko E, Ritterhoff S, Sevilla-Perez J, Roscic A, Frobius K, Kotevic I, Vichalkovski A, Hess D, Hemmings BA, Schmitz ML. 2009. PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage. Oncogene 28(5):698-708.
47. Grotzinger T, Jensen K, Will H. 1996. The interferon (IFN)- stimulated gene Sp100 promoter contains an IFN-gamma activation site and an imperfect IFN-stimulated response element which mediate type I IFN inducibility. J Biol Chem 271(41):25253-25260.
48. Guldner HH, Szostecki C, Grotzinger T, Will H. 1992. IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J Immunol 149(12):4067-4073.
49. Hayakawa F, Abe A, Kitabayashi I, Pandolfi PP, Naoe T. 2008. Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J Biol Chem 283(36):24420-24425.
50. Hayakawa F, Privalsky ML. 2004. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5(4):389-401.
51. Henderson BR, Eleftheriou A. 2000. A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. Exp Cell Res 256(1):213-224.
52. Herzer K, Weyer S, Krammer PH, Galle PR, Hofmann TG. 2005. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. Cancer Res 65(23):10830-10837.
53. Hoppe A, Beech SJ, Dimmock J, Leppard KN. 2006. Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption. J Virol 80(6):3042-3049.
54. Hwang J, Kalejta RF. 2009. Human cytomegalovirus protein pp71 induces Daxx SUMOylation. J Virol 83(13):6591-6598.
55. Iki S, Yokota S, Okabayashi T, Yokosawa N, Nagata K, Fujii N. 2005. Serum-dependent expression of promyelocytic leukemia protein suppresses propagation of influenza virus. Virology 343(1):106-115.
56. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF, 3rd, Maul GG. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147(2):221-234.
57. Jensen K, Shiels C, Freemont PS. 2001. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20(49):7223-7233.
58. Kakizuka A, Miller WH, Umesono K, Warrell RP, Frankel SR, Murty VV, Dmitrovsky E, Evans RM. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66(4):663-674.
59. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh ET. 1998. Identification of three major sentrinization sites in PML. J Biol Chem 273(41):26675-26682.
60. Kawai T, Akira S, Reed JC. 2003. ZIP kinase triggers apoptosis from nuclear PML oncogenic domains. Mol Cell Biol 23(17): 6174-6186.
61. Kentsis A, Dwyer EC, Perez JM, Sharma M, Chen A, Pan ZQ, Borden KL. 2001. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. J Mol Biol 312(4):609-623.
62. Kim TK, Lee JS, Oh SY, Jin X, Choi YJ, Lee TH, Lee E, Choi YK, You S, Chung YG, Lee JB, DePinho RA, Chin L, Kim H. 2007. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells. Cancer Res 67(23):11133-11140.
63. Kwek SS, Derry J, Tyner AL, Shen Z, Gudkov AV. 2001. Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 20(20):2587-2599.
64. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de The H. 2008. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10(5): 547-555.
65. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A, Duprez E, Pandolfi PP, Puvion E, Freemont P, de The H. 2001. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193(12):1361-1371.
66. Lee HR, Kim DJ, Lee JM, Choi CY, Ahn BY, Hayward GS, Ahn JH. 2004. Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J Virol 78(12):6527-6542.
67. Leppard KN, Emmott E, Cortese MS, Rich T. 2009. Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence in PML isoform II that is predicted as a protein interaction site by bioinformatic analysis. J Gen Virol 90(Pt 1):95-104.
68. Li W, Ferguson BJ, Khaled WT, Tevendale M, Stingl J, Poli V, Rich T, Salomoni P, Watson CJ. 2009a. PML depletion disrupts normal mammary gland development and skews the composition of the mammary luminal cell progenitor pool. Proc Natl Acad Sci U S A 106(12):4725-4730.
69. Li W, Wang G, Zhang H, Zhang D, Zeng J, Chen X, Xu Y, Li K. 2009b. Differential suppressive effect of promyelocytic leukemia protein on the replication of different subtypes/strains of influenza A virus. Biochem Biophys Res Commun 389(1): 84-89.
70. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, Chao TT, Ho CC, Chen YC, Lin TP, Fang HI, Hung CC, Suen CS, Hwang MJ, Chang KS, Maul GG, Shih HM. 2006. Role of SUMOinteracting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 24(3):341-354.
71. Lin HK, Bergmann S, Pandolfi PP. 2004. Cytoplasmic PML unction in TGF-beta signalling. Nature 431(7005):205-211.
72. Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, Grossman T, Matentzoglu K, Jiang YH, Muller S, Scheffner M, Haupt S, Haupt Y. 2009. E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ 16(8):1156-1166.
73. Marcos-Villar L, Lopitz-Otsoa F, Gallego P, Munoz-Fontela C, Gonzalez-Santamaria J, Campagna M, Shou-Jiang G, Rodriguez MS, Rivas C. 2009. Kaposis sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J Virol 83(17):8849-8858.
74. Maul GG, Guldner HH, Spivack JG. 1993. Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J Gen Virol 74 (Pt 12):2679-2690.
75. McNally BA, Trgovcich J, Maul GG, Liu Y, Zheng P. 2008. A role for cytoplasmic PML in cellular resistance to viral infection. PLoS One 3(5):e2277.
76. Meiering CD, Linial ML. 2003. The promyelocytic leukemia protein does not mediate foamy virus latency in vitro. J Virol 77(3):2207-2213.
77. Moller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Droge W, Will H, Schmitz ML. 2003. PML is required for homeodomain- interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 63(15):4310-4314.
78. Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS. 1994. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 14(10):6858-6867.
79. Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, Pandolfi PP, Dejean A. 2005. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 9(6):769-779.
80. Nefkens I, Negorev DG, Ishov AM, Michaelson JS, Yeh ET, Tanguay RM, Muller WE, Maul GG. 2003. Heat shock and Cd2 exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently. J Cell Sci 116(Pt 3): 513-524.
81. Negorev D, Maul GG. 2001. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20(49):7234-7242.
82. Negorev DG, Vladimirova OV, Maul GG. 2009. Differential functions of interferon-upregulated Sp100 isoforms: herpes simplex virus type 1 promoter-based immediate-early gene suppression and PML protection from ICP0-mediated degradation. J Virol 83(10):5168-5180.
83. Nojima T, Oshiro-Ideue T, Nakanoya H, Kawamura H, Morimoto T, Kawaguchi Y, Kataoka N, Hagiwara M. 2009. Herpesvirus protein ICP27 switches PML isoform by altering mRNA splicing. Nucleic Acids Res 37(19):6515-6527.
84. Ozato K, Shin DM, Chang TH, Morse HC, 3rd. 2008. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 8(11):849-860.
85. Pampin M, Simonin Y, Blondel B, Percherancier Y, Chelbi-Alix MK. 2006. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J Virol 80(17): 8582-8592.
86. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406(6792):207-210.
87. Pelicano L, Brumpt C, Pitha PM, Chelbi-Alix MK. 1999. Retinoic acid resistance in NB4 APL cells is associated with lack of interferon alpha synthesis Stat1 and p48 induction. Oncogene 18(27):3944-3953.
88. Perfettini JL, Nardacci R, Seror C, Bourouba M, Subra F, Gros L, Manic G, Amendola A, Masdehors P, Rosselli F, Ojcius DM, Auclair C, de The H, Gougeon ML, Piacentini M, Kroemer G. 2009. The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope. Cell Death Differ 16(2): 298-311.
89. Porta C, Hadj-Slimane R, Nejmeddine M, Pampin M, Tovey MG, Espert L, Alvarez S, Chelbi-Alix MK. 2005. Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Oncogene 24(4):605-615.
90. Preston CM, Nicholl MJ. 2006. Role of the cellular protein hDaxx in human cytomegalovirus immediate-early gene expression. J Gen Virol 87(Pt 5):1113-1121.
91. Puvion-Dutilleul F, Chelbi-Alix MK, Koken M, Quignon F, Puvion E, de The H. 1995. Adenovirus infection induces rearrangements in the intranuclear distribution of the nuclear body-associated PML protein. Exp Cell Res 218(1):9-16.
92. Regad T, Bellodi C, Nicotera P, Salomoni P. 2009. The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat Neurosci 12(2):132-140.
93. Regad T, Chelbi-Alix MK. 2001. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20(49):7274-7286.
94. Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de The H, Chelbi-Alix MK. 2001. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J 20(13):3495-3505.
95. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R. 2001. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 15(23):3088-3103.
96. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, Teruya-Feldstein J, Tempst P, Pandolfi PP. 2006. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126(2):269-283.
97. Schreiner S, Wimmer P, Sirma H, Everett RD, Blanchette P, Groitl P, Dobner T. 2010. Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirusinfected cells. J Virol 84(14):7029-7038.
98. Shah SJ, Blumen S, Pitha-Rowe I, Kitareewan S, Freemantle SJ, Feng Q, Dmitrovsky E. 2008. UBE1L represses PML/RAR {alpha} by targeting the PML domain for ISG15ylation. Mol Cancer Ther 7(4):905-914.
99. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. 2006. The mechanisms of PML-nuclear body formation. Mol Cell 24(3):331-339.
100. Stadler M, Chelbi-Alix MK, Koken MHM, Venturini L, Lee C, Saïb A, Quignon F, Pelicano L, Guillemin M-C, Schindler C, de Thé H. 1995. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 11:2565-2573.
101. Stehmeier P, Muller S. 2009. Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell 33(3):400-409.
102. Sternsdorf T, Jensen K, Will H. 1997. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol 139(7):1621-1634.
103. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427(6977):848-853.
104. Szostecki C, Guldner HH, Netter HJ, Will H. 1990. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J Immunol 145(12): 4338-4347.
105. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. 2003. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424(6948):516-523.
106. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT. 2008. RNF4 is a poly- SUMO-specific E3 ubiquitin ligase required for arsenicinduced PML degradation. Nat Cell Biol 10(5):538-546.
107. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T. 2006. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J Virol 80(16):8006-8018.
108. Tavalai N, Papior P, Rechter S, Stamminger T. 2008. Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. J Virol 82(1):126-137.
109. Tavalai N, Stamminger T. 2008. New insights into the role of the subnuclear structure ND10 for viral infection. Biochim Biophys Acta 1783(11):2207-2221.
110. Toniato E, Chen XP, Losman J, Flati V, Donahue L, Rothman P. 2002. TRIM8/GERP RING finger protein interacts with SOCS-1. J Biol Chem 277(40):37315-37322.
111. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. 2008. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4(2):e16.
112. Ullman AJ, Reich NC, Hearing P. 2007. Adenovirus E4 ORF3 protein inhibits the interferon-mediated antiviral response. J Virol 81(9):4744-4752.
113. Ullman AJ, Hearing P. 2008. Cellular proteins PML and Daxx mediate an innate antiviral defense antagonized by the adenovirus E4 ORF3 protein. J Virol 82(15):7325-7335.
114. Van Damme E, Laukens K, Dang TH, Van Ostade X. 2010. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J Biol Sci 6(1):51-67.
115. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, Pandolfi PP. 1998a. Role of PML in cell growth and the retinoic acid pathway. Science 279(5356):1547-1551.
116. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP. 1998b. PML is essential for multiple apoptotic pathways. Nat Genet 20(3):266-272.
117. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo- Fonseca M, Lamond A, Dejean A. 1994. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76(2):345-356.
118. Yang K, Shi HX, Liu XY, Shan YF, Wei B, Chen S, Wang C. 2009. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol 182(6):3782-3792.
119. Yang S, Kuo C, Bisi JE, Kim MK. 2002. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 4(11):865-870.
120. Zhu J, Gianni M, Kopf E, Honore N, Chelbi-Alix M, Koken M, Quignon F, Rochette-Egly C, de The H. 1999. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A 96(26):14807-14812.
121. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H. 1997. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94(8):3978-3983.